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Abstract
BACKGROUND
Women with gestational diabetes mellitus have an increased risk of developing
gestational hypertension, which can increase fetal and neonatal morbidity and
mortality. In the past decade, single nucleotide polymorphisms in several genes
have been identified as risk factors for development of gestational hypertension.
The epidermal growth factor receptor activates tyrosine kinase mediated blood
vessels contractility; and inflammatory cascades. Abnormalities in these
mechanism are known to contribute towards hypertension. It is thus plausible
that polymorphisms in the epidermal growth factor receptor gene would be
associated with the development of hypertension in women with gestational
diabetes.
AIM
To determine whether the epidermal growth factor receptor rs17337023 SNP is
associated with the occurrence of hypertension in gestational diabetic women.
METHODS
This pilot case-control study was conducted at two tertiary care hospitals in
Karachi, from January 2017-August 2018. Two hundred and two women at 28
week of gestation with gestational diabetes were recruited and classified into
normotensive (n = 80) and hypertensive (n = 122) groups. Their blood samples
were genotyped for epidermal growth factor receptor polymorphism rs17337023
using tetra-ARMS polymerase chain reaction. Descriptive analysis was applied
on baseline data. Polymorphism data was analyzed for genotype and allele
frequency determination using chi-squared statistics. In all cases, a P value of <
0.05 was considered significant.
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RESULTS
Subjects were age-matched and thus no difference was observed in relation to age
of the study subjects (P >0.05). Body fat percentage was significantly higher in
hypertensive females as compared to normotensive subjects (35.138 ± 4.29 Case vs
25.01 ± 8.28 Control; P < 0.05). Similarly, systolic and diastolic blood pressures
among groups were significantly higher in hypertensive group than the
normotensive group (P < 0.05). Overall epidermal growth factor receptor
rs17337023 polymorphism genotype frequency was similar in both groups, with
the heterozygous AT genotype (56 in Case vs 48 in Control; P = 0. 079) showing
predominance in both groups. Furthermore, the odds ratio for A allele was 1.282
(P = 0.219) and for T allele was 0.780 (P = 0.221) in this study.
CONCLUSION
This pilot study indicates that polymorphisms in rs17337023 may not be involved
in the pathophysiology of gestational hypertension in gestational diabetes via
inflammatory cascade mechanism. Further large-scale studies should explore
polymorphism in epidermal growth factor receptor and other genes in this
regard.
Key words: Gestational diabetes mellitus; Gestational hypertension; Epidermal growth
factor receptor; rs17337023; Single nucleotide polymorphism; Polymorphism; Case-
control
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Core tip: Gestational Hypertension (GHTN) can increase risk of fetal and neonatal
morbidity and mortality. Many environmental, nutritional and genetic factors are related
to the development of GHTN. Among them, Epidermal Growth Factor Receptor (EGFR)
has been found to contribute to arterial hypertension. It is thus plausible that Single
nucleotide polymorphisms (SNPs) in EGFR gene would be associated with the
development of GHTN in women with GDM. This pilot study indicated that EGFR
rs17337023 polymorphism may not be involved in the pathophysiology of GHTN in
GDM positive females in a local population. Further large-scale studies should explore
SNPs in EGFR and other genes in this regard.
Citation: Martins RS, Ahmed T, Farhat S, Shahid S, Fatima SS. Epidermal growth factor
receptor rs17337023 polymorphism in hypertensive gestational diabetic women: A pilot
study. World J Diabetes 2019; 10(7): 396-402
URL: https://www.wjgnet.com/1948-9358/full/v10/i7/396.htm
DOI: https://dx.doi.org/10.4239/wjd.v10.i7.396
INTRODUCTION
Gestational diabetes mellitus (GDM), defined as any degree of glucose intolerance
with onset or first recognition during pregnancy[1,2],  is a significant risk factor for
maternal development of a hypertensive pregnancy disorder (HPD)[3-5]. Up to 10% of
all pregnancies are complicated by HPDs[6,7],  especially in cases with pre-existing
GDM[8]. One type of HPD, Gestational Hypertension (GHTN) occurs in 1.8%-4.4% of
pregnancies[9]. GHTN is defined as blood pressure (BP) that reaches ≥ 140/90 mmHg
for the first-time during pregnancy (after 20 wk gestation), without proteinuria. BP
normalizes by 12 week postpartum[10]. Complications of GHTN include increased risk
for fetal death and severe neonatal morbidity and mortality[11]. Hypothesized mecha-
nisms of HPD development include dysfunction of the placenta, endothelium or lipid
metabolism,  as  well  as  inflammatory states[12].  However,  it  is  being increasingly
established that genetic factors also contribute towards HPDs[13].
Single nucleotide polymorphisms (SNPs) have been a particular focus in genetic
mechanisms leading to HPD[14].  SNPs such as NOS SNP rs2070744[15],  APM1 SNP
rs1501299[16],  CYP19A1  SNP  rs700158[17],  KDR  SNP  rs2071559[18]  and  HSD11B1
rs846910[19],  have been found to be associated with HPDs. The epidermal growth
factor receptor (EGFR) is a single chain transmembrane protein of the ErbB family of
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receptor tyrosine kinases, which is activated following binding with peptide growth
factors of the EGF-family of proteins[20]. The functions of EGFR include inducing cell
growth and differentiation[21]. EGFR is abundantly expressed in the vascular wall and
myocardium, and is thought to be linked to arterial hypertension, possibly by produc-
ing vasoconstriction and renal Na+ retention[22]. Apart from its normal EGF Ligands,
EGFR also  undergoes  transactivation by vasoactive  substances  such as  catecho-
lamines[23] and aldosterone[24]. The EGFR SNP rs17337023 (T > A), located on Exon 16
with a global variant allele frequency of 0.456[25],  is associated with chronic infla-
mmation,  which may lead to  vascular  damage and hypertension[26,27].  Given the
mechanistic link of EGFR to BP regulation, we decided to conduct a pilot study to
explore  any  association  of  SNP  rs17337023  with  the  development  of  GHTN  in
pregnant females with GDM.
MATERIALS AND METHODS
In a case-control study, n = 202 pregnant women at 28 wk of gestation with GDM
were  recruited.  The  study  was  conducted  at  Aga  Khan  University  and  Jinnah
Postgraduate Medical Center during the period of January 2017 till August 2018. The
sample size was calculated using the Open-Epi website[28], with a confidence level of
95%, power of 80%, least extreme odds ratio (OR) of 2 and a pregnancy hypertension
prevalence  of  8%  taken  according  to  previously  published  data  sources[29].  The
minimum sample size calculated for this research was n = 106. The institutional ethics
committee approved the research protocol (Ref # 4523-BBS-ERC-16) (REF: No.F.2-
81/GENL-2017-IRB/15107/JPMC). GDM was diagnosed by means of a 75-g 2-h oral
glucose tolerance test, as per the criteria set by the IADPSG[30]. All study subjects gave
a written informed consent followed by weight and body mass index (BMI) assess-
ment based on South Asian criteria for BMI values [normal weight (BMI 18-22.9
kg/m2), and obese (BMI ≥ 26kg/m2)][31]. BP assessment was done following the latest
European Society of Cardiology and the European Society of Hypertension task force
guidelines[32,33],  (Normal BP < 139/85 mmHg and Hypertension > 139/85 mmHg).
Subjects diagnosed with GHTN were subsequently being treated by antihypertensive
medication. Any individual with a history of pre-existing diabetes, or any inflamm-
atory condition, taking oral contraception or hormonal support, was not included in
this study. Based on these measurements, grouping of study subjects was done as
follow: (A) Normotensive (n = 80); (B) Hypertensive (n = 122) (on diet or medication).
Ten  milliliters  of  venous  blood  were  collected  from  each  subject.  DNA  was
extracted from whole blood by Qiagen DNA extraction kit (Cat. #51185, Valencia, CA,
United States). The quantification of extracted DNA was performed by measuring the
ultraviolet absorbance of the samples using a Nanodrop-ND1000 (Thermo Fisher
Scientific, Waltham, MA). The absorbance ratio (A280/A260) was determined for 2 μL
samples using ND-1000 V3.8.1 software (Thermo Fisher Scientific, Waltham, MA). A
ratio of approximately 1.8 was considered acceptable for confirming the purity of
extracted DNA. Furthermore, around 10% of samples were confirmed on gel electro-
phoresis by running 1 μL of sample in a 1% agarose gel against a 1 kb ladder. Tetra
arms polymerase  chain reaction (PCR) was performed using the  Ruby Taq PCR
Master mix 2X (Cat. #71191, Affymetrix, United States) as per the manufacturer’s
instructions. PCR products were electrophoresed in a 2% agarose gel. Genotyping
quality control was performed in 10% of the samples by duplicate checking (rate of
concordance in duplicates was > 99 %). The following primer set was used for gene
amplification: Statistical analyses were conducted using the IBM Statistical Package
for  the  Social,  Sciences  (IBM  SPSS  version  21;  IBM  Corp  Inc,  Armonk,  NY).
Descriptive analysis was applied, and data was expressed either as mean ± standard
deviation or absolute number and percentage. SNP data was analysed for genotype
and allele frequency determination by applying chi-squared statistics. In all situations
a P value of < 0.05 was considered significant. The statistical analyses for this study
were performed and reviewed by Syed Adnan Ali (PhD. Statistics) of the University
of Karachi.
RESULTS
The detailed results are shown in Table 1, 2 and Figure 1. All study subjects were age-
matched and therefore, no difference was observed in relation to age of the study
subjects (P  > 0.05).  Body fat  percentage was significantly higher in hypertensive
females as compared to normotensive subjects  (P  < 0.05).  Similarly,  systolic  and
diastolic BP among were significantly higher in hypertensive group than the normo-
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tensive group (P < 0.05). 90% of the hypertensive females practiced sedentary lifestyle
versus 17.7% normotensive females (P < 0.05).
Overall EGFR rs17337023 polymorphism genotype frequency was similar in both
the normotensive and hypertensive groups,  with the heterozygous AT genotype
showing predominance in both groups. Furthermore, the OR for A allele was 1.282 (P
= 0.219) and for T allele was 0.780 (P = 0.221) in this study.
DISCUSSION
The developmental causes of GHTN in women with pre-existing GDM is poorly
understood and it is possible that genetic factors such as SNPs may play a role. Many
studies have demonstrated associations of certain SNPs with development of HPDs.
Our objective was to investigate whether the EGFR SNP rs17337023 displayed any
significant association with the occurrence of GHTN in pregnant women with GDM.
However, the findings of our study showed that the frequency of the rs17337023
genotype was not significantly different in the two groups. Furthermore, the OR for
the A and T alleles were also non-significant.  These results suggest that the SNP
rs17337023 does not play any major role in the pathophysiology of GHTN in GDM.
There are possible explanations for the lack of any significant association. The
study proposing mechanisms linking EGFR to arterial hypertension does so primarily
on the basis of results obtained from experimenting using animal models, and voices
uncertainties about its applicability to humans[22]. Moreover, apart from Rheumatoid
Arthritis, the SNP rs17337023 has been shown to have no significant association with
pathologies such as Gastric Carcinoma[34]  and Nasopharyngeal Carcinoma[35].  This
suggests that the function of EGFR is not altered significantly enough due to the SNP
rs17337023 mutation to cause any major pathological state. It is possible, however,
that other EGFR SNPs may indeed be associated with GHTN in women with GDM.
Additionally, since the sample for our pilot study consisted of 202 women from
Pakistan, it is possible that the results may show greater significance if the study were
replicated in another population with a larger sample size. The lack of association
between the EGFR SNP rs17337023 served to suggest that the EGFR gene may not be
involved in the pathophysiology of GHTN in the case of pre-existing GDM. Our study
was limited by the inability to recruit a larger sample size due to cultural beliefs and
barriers towards participation in genetic studies. Moreover, the group of women with
GHTN were not managed uniformly in terms of diet and antihypertensive medi-
cations.  Nevertheless,  the  rs17337023  polymorphism  was  in  Hardy-Weinberg
Equilibrium for cases and controls, suggesting the randomness of the sample as a
strength of our study.
This pilot study indicates that polymorphisms in rs17337023 may not be involved
in  the  pathophysiology  of  gestational  hypertension  in  gestational  diabetes  via
inflammatory  cascade  mechanism.  Further  large-scale  studies  should  explore
polymorphism in epidermal growth factor receptor and other genes in this regard.
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Table 1  Polymerase chain reaction primers details
Gene Primers Base pairs PCR cycle Amplicon Size
Epidermal growth factor
receptor (EGFR) rs17337023
Forward outer:
ATTAACCACCAATCCAAC
ATCCAGAC
26 67 °C; 30 s; 30 cycles T allele 180; C allele 271;
Control 406
Reverse outer:
CTTTCCCTCCACTGAGGA
CAAAGTT
25
Forward inner (A allele):
TCTCTTTCACTTCCTACAG
ATGCTCA
26
Reverse inner (T allele):
AGCCTTCAAGACCTGGCG
CA
20
PCR: Polymerase chain reaction.
Table 2  Descriptive statistics and genotype frequency of study subjects
Hypertensive pregnant case (n = 122) Normotensive pregnant control (n = 80) P-value
Age (Yr) 30.55 ± 8.05 29.13 ± 10.19 0.054
Weight (kg) 77.56 ± 16.88 69.24 ± 11.07 0.025
Body Fat % 35.138 ± 4.29 25.01 ± 8.28 0.000
Waist circumference (cm) 104.50 ± 12.09 86.92 ± 12.03 0.000
Systolic blood pressure (mmHg) 131.76 ± 13.04 122.02 ± 8.27 0.000
Diastolic blood pressure (mmHg) 85.88 ± 8.45 73.31 ± 11.27 0.000
Walk
None 90.1% 17.7% 0.000
30 min/3 days week 7.9% 74.2%
30 min/5 days week 2.0% 8.1%
Genotype frequency
EGFR rs17337023 polymorphism
AA 30 19 0.079
AT 56 48
TT 36 13
Allele Odds Ratio
Allele A 1.282 [0.860-1.912] 0.219
Allele T 0.780 [0.523-1.163] 0.221
Data presented as Mean ± SD and percentages. In all cases a P value of < 0.05 was considered significant. Hardy-Weinberg Equilibrium (HWE) for case P =
0.378 and control P = 0.064, Where EGFR is epidermal growth factor receptor.
Figure 1
Figure 1  Gel Electrophoresis of epidermal growth factor receptor samples 1 to 8 cases and 1 to 9 Controls. B is blank, and M is the 100bp ladder. Tetra arms
control band is visible at 406bp; C allele at 271bp and T allele at 180bp.
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ARTICLE HIGHLIGHTS
Research background
Pregnancy induced hypertension and diabetes are an increasing threat to the wellbeing of both
mother and the baby. The basic pathophysiological link to disease predisposition is attributed to
the functionality of epidermis and angiogenesis. Several genetic studies have provided evidence
that epidermal growth factor dysfunction can lead to hypertension and its complications in preg-
nancy.
Research motivation
Materno-fetal mortality is on the rise in lower middle income countries; predominantly due to
lack of primary prevention of non-communicable diseases. This led us to investigate one of the
route cause i.e. genetic modification as a risk for development of disease.
Research objectives
Explore any association of SNP rs17337023 with the development of gestational hypertension in
pregnant females with gestational diabetes.
Research methods
A case-control study was conducted recruiting 202 pregnant women at 28 wk of gestation. Their
blood pressure, blood glucose levels were measures and genotyping of EGFR SNP rs17337023
was performed via tetra arms PCR.
Research results
No difference was seen in the EGFR rs17337023 polymorphism genotype frequency among both
normotensive and hypertensive groups in this study.
Research conclusions
This  pilot  study  indicates  that  polymorphisms  in  rs17337023  may  not  be  involved  in  the
pathophysiology of gestational hypertension in gestational diabetes. Further large-scale studies
should explore polymorphism in epidermal growth factor receptor and other genes in this
regard.
Research perspectives
This study has shown some negative results linking a specific area of the gene EGFR; however, it
should be noted that other factors may also be in play such as obesity and family history that can
be a contributing factor along with genetic predisposition for hypertension. This opens up new
avenues for researchers to perform prospective studies to identify the causal  link between
genetic and environmental factors.
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